[시장보고서]세계의 생체흡수성 폴리머 시장 : 유형별, 용도별, 지역별

세계의 생체흡수성 폴리머 시장 : 유형별, 용도별, 지역별 - 예측(-2029년)

Bioresorbable Polymers Market by Type (Polylactic Acid (PLA), Polyglycolic Acid (PGA), Polylactic-co-glycolic acid (PLGA), Polycaprolactone (PCL)), Application (Orthopedic Devices, Drug Delivery), and Region - Global Forecast to 2029

상품코드 : 1603239 해당 상품은 즉시 배송 가능합니다

리서치사 : MarketsandMarkets

발행일 : 2024년 11월

페이지 정보 : 영문 222 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 7,146,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650

￦ 9,601,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150

￦ 11,766,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,438,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

생체흡수성 폴리머 시장 규모는 11.6%의 CAGR로 확대되어 2024년 5억 달러에서 2029년 8억 6,720만 달러로 성장할 것으로 예상됩니다.

보건의료 산업에 대한 정부의 우호적인 규제와 정책은 생체흡수성 폴리머 시장에 긍정적인 영향을 미치고 있습니다. 여러 국가에서 정형외과용 기구와 같은 의료기기의 생체적합성과 생분해성을 높이기 위해 제조업체를 장려하는 규제를 시행하고 있습니다. 이러한 변화는 생체흡수성 폴리머의 생산을 촉진하고 있습니다. 수술용 임플란트 신기술이 생체흡수성 폴리머에 대한 수요를 촉진하고 있습니다. 이는 기업들이 생흡수성 고분자 시장에 더 많은 투자를 하도록 유도하고 있습니다.

조사 범위
조사 대상 연도	2019-2029년
기준 연도	2023년
예측 기간	2024-2029년
대상 단위	금액(100만 달러) 및 수량(개)
부문	유형별, 용도별, 지역별
대상 지역	아시아태평양, 유럽, 북미, 중동 및 아프리카, 남미

PCL 유형 부문은 예측 기간 동안 생체흡수성 폴리머 시장에서 세 번째로 빠르게 성장할 것으로 예상됩니다. 이러한 수요는 주로 약물전달 시스템에서의 수요에 기인하며, PCL은 생체적합성과 유연성으로 인해 주사 가능한 마이크로 입자, 이식형 장치, 캡슐 등 모든 약물전달 형태에 유연하게 적용될 수 있습니다. 다른 생체흡수성 폴리머와의 호환성 덕분에 PCL은 첨단 치료 시스템에서 맞춤형 제제를 위한 첫 번째 선택이 되고 있습니다.

약물전달 분야는 생체흡수성 폴리머 시장에서 두 번째로 큰 응용 분야로 자리매김하고 있습니다. 이러한 수요는 환자 치료 결과를 개선하기 위해 제어되고 표적화된 서방형 약물 시스템에 대한 필요성에 의해 촉진되고 있습니다. 생체흡수성 폴리머는 이식 가능한 약물 매트릭스 및 캡슐을 제조하는 데도 널리 사용되고 있으며, 이는 치료제를 장기간에 걸쳐 천천히 제어된 방출을 가능하게 합니다. 이를 통해 재투여의 필요성을 없애고 환자의 불편함을 크게 줄일 수 있습니다. 이 폴리머는 생체적합성이 뛰어나 체내에서 안전하게 분해되어 혁신적이고 환자 중심의 의료 솔루션을 추구하는 의료 산업 트렌드에 부합합니다. 전 세계적으로 첨단 약물전달 시스템에 대한 요구가 증가함에 따라, 생체흡수성 폴리머는 효율적이고 효과적인 치료 솔루션을 만드는 데 있어 가장 중요한 선택지 중 하나가 되고 있습니다.

2023년 생체흡수성 폴리머 시장에서 유럽은 금액 기준으로 두 번째로 큰 시장입니다. 이 지역의 생흡수성 고분자 시장은 비교적 성숙한 시장으로 아시아태평양 및 남미 신흥국 시장보다 성장 속도가 느립니다. 유럽의 생체흡수성 폴리머 수요는 주로 암, 심혈관질환, 정형외과 질환, 신경 질환과 같은 만성질환의 유병률 증가에 기인합니다. 유럽에서는 비만, 외상, 정형외과, 심혈관 수술도 증가하고 있습니다. 이 지역은 강력한 의료 인프라를 갖추고 있으며, 첨단 의료 연구 수준을 더욱 높이고 있습니다. 이는 임플란트 및 약물전달 시스템을 위한 지속가능하고 생체적합성이 높은 솔루션으로 제공되는 생체흡수성 폴리머 시장을 분명히 강화하고 있습니다. 또한, 생분해성 소재 기반 의료기기에 대한 규제 당국의 지원도 유럽 시장으로의 확산을 촉진하고 있습니다.

이 보고서는 세계 생체흡수성 폴리머 시장을 조사하여 유형별, 용도별, 지역별 동향, 시장 진입 기업 개요 등을 정리한 보고서입니다.

공급망 분석
가격 분석
고객 비즈니스에 영향을 미치는 동향/혼란
생태계 분석
기술 분석
사례 연구 분석
무역 분석
규제 상황
2024-2025년의 주요 회의와 이벤트
투자와 자금 조달 시나리오
특허 분석
AI/생성형 AI가 생체흡수성 폴리머 시장에 미치는 영향

제7장 생체흡수성 폴리머 시장(유형별)

소개
폴리젖산(PLA)
폴리글리콜산(PGA)
폴리(젖산-글리콜산)(PLGA)
폴리카프로락톤(PCL)
기타

제8장 생체흡수성 폴리머 시장(용도별)

소개
정형외과용 기기
약물전달
기타

제9장 생체흡수성 폴리머 시장(지역별)

소개
북미
- 미국
- 캐나다
- 멕시코
아시아태평양
- 중국
- 일본
- 인도
- 한국
유럽
- 독일
- 영국
- 이탈리아
- 프랑스
- 러시아
중동 및 아프리카
- 중동
- 아프리카
남미
- 브라질
- 아르헨티나

제10장 경쟁 상황

소개
주요 진출 기업 전략/강점
시장 점유율 분석
매출 분석
기업 평가 매트릭스 : 주요 진출 기업, 2023년
기업 평가 매트릭스 : 스타트업/중소기업, 2023년
브랜드/제품 비교
기업 가치 평가와 재무 지표
경쟁 시나리오

제11장 기업 개요

주요 진출 기업
- CORBION
- EVONIK INDUSTRIES AG
- FOSTER CORPORATION
- KLS MARTIN GROUP
- DSM BIOMEDICAL
- ASHLAND GLOBAL HOLDINGS INC.
- ZEUS COMPANY LLC
- SEQENS
- REVA MEDICAL, LLC
- POLY-MED INCORPORATED
기타 기업
- BEZWADA BIOMEDICAL, LLC
- NOMISMA HEALTHCARE PVT. LTD.
- BMG INC.
- POLYSCIENCES, INC.
- HUIZHOU FORYOU MEDICAL DEVICES CO., LTD.
- MUSASHINO CHEMICAL LABORATORY, LTD.
- HENAN XINGHAN BIOLOGICAL TECHNOLOGY CO., LTD.

제12장 인접 시장과 관련 시장

제13장 부록

ksm

영문 목차

영문목차

In terms of value, the bioresorbable polymers market is estimated to grow from USD 500.0 million in 2024 to USD 867.2 million by 2029, at a CAGR of 11.6%. Favorable regulations and policies by the government towards healthcare industry are positively influencing the bioresorbable polymers market. Various countries have created regulations that encourage manufacturers to increase biocompatibility & biodegradability of medical devices like orthopedic devices. These changes promote the creation of bioresorbable polymers. New technologies for the surgical implants are driving the demand for bioresorbable polymers. This further encourages businesses to invest in the bioresorbable polymers market.

Scope of the Report
Years Considered for the Study	2019-2029
Base Year	2023
Forecast Period	2024-2029
Units Considered	Value (USD Million) and Volume (Unit)
Segments	Type, Application, and Region
Regions covered	Asia Pacific, Europe, North America, Middle East & Africa, and South America

"PCL type segment is projected to be the third-fastest growing segment of bioresorbable polymers market, during the forecast period"

PCL type segment is estimated to be the third-fastest growing segment of bioresorbable polymers market, during the forecast period. This demand is primarily due to its demand in drug delivery systems. The properties of biocompatibility and flexibility make PCL flexible and capable for use in any drug delivery format, such as injectable microparticles, implantable devices, and capsules. Compatibility with other bioresorbable polymers brings it as the first choice for customized formulations in advanced therapeutic systems.

"Drug delivery was the second largest end-use industry of bioresorbable polymers market, in terms of value, in 2023."

Drug delivery segment stands as the second-largest application in the bioresorbable polymers market. The demand is fueled by the need of controlled, targeted, and sustained-release drug systems, resulting in improved patient outcomes. Bioresorbable polymers are also widely employed in the preparation of implantable drug matrices and capsules to provide a slow and controlled release of therapeutic agents over time. This avoids the need for re-dose, thus significantly reducing discomfort to the patient. Their biocompatibility ensures that these polymers degrade safely within the body, well in line with the increasing trend by the medical industry towards innovative, patient-centered care solutions. With the desire for advanced drug delivery systems all over the world on the rise, bioresorbable polymers are among the most important choices when making efficient and effective therapeutic solutions.

"Europe was the second largest region in the bioresorbable polymers market, in terms of value."

Europe was the second-largest region in the bioresorbable polymers market, in terms of value, in 2023. The bioresorbable polymers market in the region is comparatively mature, growing slower than the developing markets in the Asia-Pacific region and South America. The demand of bioresorbable polymers in the European region is primarily due to the increasing prevalence of chronic diseases such as cancers, cardiovascular diseases, orthopedic disorders, and neurological conditions. Bariatric, trauma, orthopedic, and cardiovascular surgical procedures are also on the rise in Europe. The region has developed a strong health care infrastructure and increased the level of advanced medical research further, which has clearly enhanced this market for bioresorbable polymers offered as sustainable and biocompatible solutions for implants and drug delivery systems. Additionally, the support by regulatory towards biodegradable material-based medical devices helps to spread across the European market.

By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
By Designation: Directors - 50%, Managers - 30%, and Others - 20%
By Region: North America - 40%, Europe - 35%, Asia Pacific - 20%, Rest of World - 5%

The key players profiled in the report include Corbion (Netherlands), Evonik Industries AG (Germany), Foster Corporation (US), KLS Martin Group (Germany), DSM Biomedical (US), Ashland Global Holdings Inc. (US), Zeus Company LLC (US), Seqens (France), Reva Medical, LLC (US), and Poly-Med Incorporated (US).

Research Coverage

This report segments the market for bioresorbable polymers based on type, application, and region and provides estimations of value (USD Million) for the overall market size across various regions. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, services, and key strategies, associated with the market for bioresorbable polymers.

Reasons to Buy this Report

This research report is focused on various levels of analysis - industry analysis (industry trends), market share analysis of top players, and company profiles, which together provide an overall view of the competitive landscape, emerging and high-growth segments of the bioresorbable polymers market; high-growth regions; and market drivers, restraints, and opportunities.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on bioresorbable polymers offered by top players in the global market
Analysis of key drivers: (Increasing number of surgical interventions, Boost in demand of biocompatible medical devices, Growing demand in drug delivery application, Favorable reimbursement scenario), opportunities (Electrospinning and 3D Printing Technologies), and challenges (Stringent regulatory framework for medical devices)
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the bioresorbable polymers market
Market Development: Comprehensive information about lucrative emerging markets - the report analyzes the markets for bioresorbable polymers across regions.
Market Diversification: Exhaustive information about new products, untapped regions, and recent developments in the global bioresorbable polymers market
Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of leading players in the bioresorbable polymers market

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 DEFINITION AND INCLUSIONS, BY TYPE
- 1.3.4 DEFINITION AND INCLUSIONS, BY APPLICATION
- 1.3.5 YEARS CONSIDERED
- 1.3.6 CURRENCY CONSIDERED
- 1.3.7 UNITS CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
  - 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY DATA
  - 2.1.2.1 Interviews with experts - demand and supply sides
  - 2.1.2.2 Key data from primary sources
  - 2.1.2.3 Key industry insights
  - 2.1.2.4 Breakdown of interviews with experts
2.2 MARKET SIZE ESTIMATION
- 2.2.1 TOP-DOWN APPROACH
- 2.2.2 BOTTOM-UP APPROACH
2.3 GROWTH FORECAST
- 2.3.1 SUPPLY-SIDE FORECAST
- 2.3.2 DEMAND-SIDE FORECAST
2.4 FACTOR ANALYSIS
2.5 DATA TRIANGULATION
2.6 RESEARCH ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 SIGNIFICANT OPPORTUNITIES FOR PLAYERS IN BIORESORBABLE POLYMERS MARKET
4.2 BIORESORBABLE POLYMERS MARKET, BY REGION
4.3 NORTH AMERICA: BIORESORBABLE POLYMERS MARKET, BY TYPE AND COUNTRY
4.4 BIORESORBABLE POLYMERS MARKET, BY APPLICATION AND REGION
4.5 BIORESORBABLE POLYMERS MARKET ATTRACTIVENESS

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Increasing number of surgical interventions
  - 5.2.1.2 Rising demand for biocompatible medical devices
  - 5.2.1.3 Growing demand for drug delivery applications
  - 5.2.1.4 Favorable reimbursement scenario
- 5.2.2 RESTRAINTS
  - 5.2.2.1 Increasing preference for minimally invasive surgeries
  - 5.2.2.2 Higher cost of bioresorbable polymers than conventional polymers
  - 5.2.2.3 Lack of quality control measures in emerging countries
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 Electrospinning and 3D printing technologies
- 5.2.4 CHALLENGES
  - 5.2.4.1 Stringent regulatory framework for medical devices
  - 5.2.4.2 Requirement of skilled personnel for effective use of bioresorbable medical products
5.3 PORTER'S FIVE FORCES ANALYSIS
- 5.3.1 THREAT OF NEW ENTRANTS
- 5.3.2 THREAT OF SUBSTITUTES
- 5.3.3 BARGAINING POWER OF SUPPLIERS
- 5.3.4 BARGAINING POWER OF BUYERS
- 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.4.2 BUYING CRITERIA
5.5 MACROECONOMIC INDICATORS
- 5.5.1 GDP TRENDS AND FORECAST OF MOST PROMINENT ECONOMIES

6 INDUSTRY TRENDS

6.1 SUPPLY CHAIN ANALYSIS
- 6.1.1 RAW MATERIAL SUPPLIERS
- 6.1.2 MANUFACTURERS
- 6.1.3 DISTRIBUTORS
- 6.1.4 END-USE INDUSTRIES
6.2 PRICING ANALYSIS
- 6.2.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION
- 6.2.2 AVERAGE SELLING PRICE TREND, BY REGION
6.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
6.4 ECOSYSTEM ANALYSIS
6.5 TECHNOLOGY ANALYSIS
- 6.5.1 KEY TECHNOLOGIES
  - 6.5.1.1 Electrospinning technology in bioresorbable polymers
- 6.5.2 COMPLEMENTARY TECHNOLOGIES
  - 6.5.2.1 Melt extrusion technology
6.6 CASE STUDY ANALYSIS
- 6.6.1 BIORESORBABLE POLYMER SCAFFOLDS FOR TISSUE ENGINEERING
- 6.6.2 BIORESORBABLE MATERIALS FOR CARDIOVASCULAR DEVICES
- 6.6.3 BIORESORBABLE 3D-PRINTED PATIENT-SPECIFIC IMPLANTS FOR CRANIO-MAXILLOFACIAL SURGERY
6.7 TRADE ANALYSIS
- 6.7.1 IMPORT SCENARIO (HS CODE 390770)
- 6.7.2 EXPORT SCENARIO (HS CODE 390770)
6.8 REGULATORY LANDSCAPE
- 6.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 6.8.2 REGULATORY FRAMEWORK
  - 6.8.2.1 Regulations impacting bioresorbable polymers business
  - 6.8.2.2 FDA guidelines for bioabsorbable polymers in medical devices
  - 6.8.2.3 REACH (Registration, evaluation, authorization and restriction of chemicals)
  - 6.8.2.4 ISO 10993 (Biological evaluation of medical devices)
  - 6.8.2.5 EU medical device regulation (MDR) for bioresorbable polymers
  - 6.8.2.6 ASTM standards for absorbable polymers and implants
6.9 KEY CONFERENCES AND EVENTS, 2024-2025
6.10 INVESTMENT AND FUNDING SCENARIO
6.11 PATENT ANALYSIS
- 6.11.1 APPROACH
- 6.11.2 PATENT TYPES
- 6.11.3 TOP APPLICANTS
- 6.11.4 JURISDICTION ANALYSIS
6.12 IMPACT OF AI/GEN AI ON BIORESORBABLE POLYMERS MARKET

7 BIORESORBABLE POLYMERS MARKET, BY TYPE

7.1 INTRODUCTION
7.2 POLYLACTIC ACID (PLA)
- 7.2.1 RISING DEMAND FOR ORTHOPEDIC DEVICES TO DRIVE MARKET
7.3 POLYGLYCOLIC ACID (PGA)
- 7.3.1 USE IN SUTURES AND OTHER MEDICAL IMPLANTS TO PROPEL MARKET
7.4 POLY (LACTIC-CO-GLYCOLIC ACID) (PLGA)
- 7.4.1 BIOCOMPATIBILITY AND BIODEGRADABILITY TO DRIVE MARKET
7.5 POLYCAPROLACTONE (PCL)
- 7.5.1 DRUG DELIVERY, TISSUE ENGINEERING, AND ORTHOPEDIC DEVICE APPLICATIONS TO DRIVE MARKET
7.6 OTHER TYPES

8 BIORESORBABLE POLYMERS MARKET, BY APPLICATION

8.1 INTRODUCTION
8.2 ORTHOPEDIC DEVICES
- 8.2.1 HIGH CONSUMPTION IN NORTH AMERICA AND EUROPE TO DRIVE MARKET
8.3 DRUG DELIVERY
- 8.3.1 SIGNIFICANT DEMAND FOR ORAL CAPSULES TO DRIVE MARKET
8.4 OTHER APPLICATIONS

9 BIORESORBABLE POLYMERS MARKET, BY REGION

9.1 INTRODUCTION
9.2 NORTH AMERICA
- 9.2.1 US
  - 9.2.1.1 Growing demand for orthopedic devices and drug delivery applications to drive market
- 9.2.2 CANADA
  - 9.2.2.1 Increasing geriatric population to boost demand
- 9.2.3 MEXICO
  - 9.2.3.1 Rising medical tourism to propel market growth
9.3 ASIA PACIFIC
- 9.3.1 CHINA
  - 9.3.1.1 Economic growth to be major driver for market growth
- 9.3.2 JAPAN
  - 9.3.2.1 Rapidly aging population to drive market
- 9.3.3 INDIA
  - 9.3.3.1 Growing pharmaceutical and medical industries to drive market
- 9.3.4 SOUTH KOREA
  - 9.3.4.1 Increasing access to healthcare facilities to drive market
9.4 EUROPE
- 9.4.1 GERMANY
  - 9.4.1.1 Established healthcare industry and technological advancements offer opportunities for market growth
- 9.4.2 UK
  - 9.4.2.1 Increasing healthcare expenditure to drive market growth
- 9.4.3 ITALY
  - 9.4.3.1 Orthopedic and pharmaceutical applications to propel market
- 9.4.4 FRANCE
  - 9.4.4.1 Initiatives to boost healthcare sector to drive demand
- 9.4.5 RUSSIA
  - 9.4.5.1 Orthopedics, healthcare, and pharmaceutical segments contribute significantly to market growth
9.5 MIDDLE EAST & AFRICA
- 9.5.1 MIDDLE EAST
  - 9.5.1.1 Improving healthcare infrastructure to drive market
- 9.5.2 AFRICA
  - 9.5.2.1 South Africa to be largest market
9.6 SOUTH AMERICA
- 9.6.1 BRAZIL
  - 9.6.1.1 Rising demand for implants in surgeries to drive market
- 9.6.2 ARGENTINA
  - 9.6.2.1 Investments by major players to drive market

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.3 MARKET SHARE ANALYSIS
10.4 REVENUE ANALYSIS
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 10.5.1 STARS
- 10.5.2 EMERGING LEADERS
- 10.5.3 PERVASIVE PLAYERS
- 10.5.4 PARTICIPANTS
- 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
  - 10.5.5.1 Company footprint
  - 10.5.5.2 Type footprint
  - 10.5.5.3 Application footprint
  - 10.5.5.4 Region footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 10.6.1 PROGRESSIVE COMPANIES
- 10.6.2 RESPONSIVE COMPANIES
- 10.6.3 DYNAMIC COMPANIES
- 10.6.4 STARTING BLOCKS
- 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  - 10.6.5.1 Detailed list of key startups/SMEs
  - 10.6.5.2 Competitive benchmarking of key startups/SMEs
10.7 BRAND/PRODUCT COMPARISON
10.8 COMPANY VALUATION AND FINANCIAL METRICS
10.9 COMPETITIVE SCENARIO
- 10.9.1 PRODUCT LAUNCHES
- 10.9.2 DEALS
- 10.9.3 EXPANSIONS

11 COMPANY PROFILES

11.1 KEY PLAYERS
- 11.1.1 CORBION
  - 11.1.1.1 Business overview
  - 11.1.1.2 Products/Solutions/Services offered
  - 11.1.1.3 Recent developments
    - 11.1.1.3.1 Deals
  - 11.1.1.4 MnM view
    - 11.1.1.4.1 Right to win
    - 11.1.1.4.2 Strategic choices
    - 11.1.1.4.3 Weaknesses and competitive threats
- 11.1.2 EVONIK INDUSTRIES AG
  - 11.1.2.1 Business overview
  - 11.1.2.2 Products/Solutions/Services offered
  - 11.1.2.3 Recent developments
    - 11.1.2.3.1 Expansions
    - 11.1.2.3.2 Deals
  - 11.1.2.4 MnM view
    - 11.1.2.4.1 Right to win
    - 11.1.2.4.2 Strategic choices
    - 11.1.2.4.3 Weaknesses and competitive threats
- 11.1.3 FOSTER CORPORATION
  - 11.1.3.1 Business overview
  - 11.1.3.2 Products/Solutions/Services offered
  - 11.1.3.3 MnM view
    - 11.1.3.3.1 Right to win
    - 11.1.3.3.2 Strategic choices
    - 11.1.3.3.3 Weaknesses and competitive threats
- 11.1.4 KLS MARTIN GROUP
  - 11.1.4.1 Business overview
  - 11.1.4.2 Products/Solutions/Services offered
  - 11.1.4.3 MnM view
    - 11.1.4.3.1 Right to win
    - 11.1.4.3.2 Strategic choices
    - 11.1.4.3.3 Weaknesses and competitive threats
- 11.1.5 DSM BIOMEDICAL
  - 11.1.5.1 Business overview
  - 11.1.5.2 Products/Solutions/Services offered
  - 11.1.5.3 MnM view
    - 11.1.5.3.1 Right to win
    - 11.1.5.3.2 Strategic choices
    - 11.1.5.3.3 Weaknesses and competitive threats
- 11.1.6 ASHLAND GLOBAL HOLDINGS INC.
  - 11.1.6.1 Business overview
  - 11.1.6.2 Products/Solutions/Services offered
  - 11.1.6.3 Recent developments
    - 11.1.6.3.1 Product launches
    - 11.1.6.3.2 Expansions
- 11.1.7 ZEUS COMPANY LLC
  - 11.1.7.1 Business overview
  - 11.1.7.2 Products/Solutions/Services offered
  - 11.1.7.3 Recent developments
    - 11.1.7.3.1 Product launches
- 11.1.8 SEQENS
  - 11.1.8.1 Business overview
  - 11.1.8.2 Products/Solutions/Services offered
- 11.1.9 REVA MEDICAL, LLC
  - 11.1.9.1 Business overview
  - 11.1.9.2 Products/Solutions/Services offered
- 11.1.10 POLY-MED INCORPORATED
  - 11.1.10.1 Business overview
  - 11.1.10.2 Products/Solutions/Services offered
11.2 OTHER PLAYERS
- 11.2.1 BEZWADA BIOMEDICAL, LLC
- 11.2.2 NOMISMA HEALTHCARE PVT. LTD.
- 11.2.3 BMG INC.
- 11.2.4 POLYSCIENCES, INC.
- 11.2.5 HUIZHOU FORYOU MEDICAL DEVICES CO., LTD.
- 11.2.6 MUSASHINO CHEMICAL LABORATORY, LTD.
- 11.2.7 HENAN XINGHAN BIOLOGICAL TECHNOLOGY CO., LTD.

12 ADJACENT AND RELATED MARKETS

12.1 INTRODUCTION
12.2 LIMITATIONS
12.3 POLY LACTIC ACID MARKET
- 12.3.1 MARKET DEFINITION
- 12.3.2 MARKET OVERVIEW
12.4 POLY LACTIC ACID MARKET, BY REGION
- 12.4.1 EUROPE
- 12.4.2 NORTH AMERICA
- 12.4.3 ASIA PACIFIC
- 12.4.4 SOUTH AMERICA
- 12.4.5 MIDDLE EAST & AFRICA

13 APPENDIX

13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS